These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27507833)

  • 1. Managing fatigue in sarcoidosis - A systematic review of the evidence.
    Atkins C; Wilson AM
    Chron Respir Dis; 2017 May; 14(2):161-173. PubMed ID: 27507833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility study of a randomised controlled trial to investigate the treatment of sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol.
    Atkins C; Fordham R; Clark AB; Stockl A; Jones AP; Wilson AM
    BMJ Open; 2017 Dec; 7(12):e018532. PubMed ID: 29208618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.
    Lower EE; Malhotra A; Surdulescu V; Baughman RP
    J Pain Symptom Manage; 2013 Feb; 45(2):159-69. PubMed ID: 22917711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
    Mustian KM; Alfano CM; Heckler C; Kleckner AS; Kleckner IR; Leach CR; Mohr D; Palesh OG; Peppone LJ; Piper BF; Scarpato J; Smith T; Sprod LK; Miller SM
    JAMA Oncol; 2017 Jul; 3(7):961-968. PubMed ID: 28253393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatments for fatigue associated with palliative care.
    Peuckmann V; Elsner F; Krumm N; Trottenberg P; Radbruch L
    Cochrane Database Syst Rev; 2010 Nov; (11):CD006788. PubMed ID: 21069692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.
    Crommelin HA; van der Burg LM; Vorselaars AD; Drent M; van Moorsel CH; Rijkers GT; Deneer VH; Grutters JC
    Respir Med; 2016 Jun; 115():72-7. PubMed ID: 27215507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.
    Erckens RJ; Mostard RL; Wijnen PA; Schouten JS; Drent M
    Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):713-20. PubMed ID: 22119879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis.
    Wagner MT; Marion SD; Judson MA
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct; 22(3):235. PubMed ID: 16315789
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
    Baughman RP; Lower EE; Drent M
    Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of fatigue: modafinil, methylphenidate, and goals of care.
    Reineke-Bracke H; Radbruch L; Elsner F
    J Palliat Med; 2006 Oct; 9(5):1210-4. PubMed ID: 17040162
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis.
    Chow R; Bruera E; Sanatani M; Chiu L; Prsic E; Boldt G; Lock M
    BMJ Support Palliat Care; 2023 Sep; 13(3):274-280. PubMed ID: 34593386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor.
    Gehring K; Patwardhan SY; Collins R; Groves MD; Etzel CJ; Meyers CA; Wefel JS
    J Neurooncol; 2012 Mar; 107(1):165-74. PubMed ID: 21964738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TNFα blocking agents and sarcoidosis: an update].
    Toussirot E; Pertuiset E
    Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.